JP2000513351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000513351A5 JP2000513351A5 JP1998502558A JP50255898A JP2000513351A5 JP 2000513351 A5 JP2000513351 A5 JP 2000513351A5 JP 1998502558 A JP1998502558 A JP 1998502558A JP 50255898 A JP50255898 A JP 50255898A JP 2000513351 A5 JP2000513351 A5 JP 2000513351A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9613182.6A GB9613182D0 (en) | 1996-06-24 | 1996-06-24 | Method |
| GB9613182.6 | 1996-06-24 | ||
| PCT/GB1997/001722 WO1997049409A1 (en) | 1996-06-24 | 1997-06-24 | Chelating agents and their metal chelates for treating free radicals induced conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000513351A JP2000513351A (ja) | 2000-10-10 |
| JP2000513351A5 true JP2000513351A5 (enExample) | 2005-02-10 |
| JP4162263B2 JP4162263B2 (ja) | 2008-10-08 |
Family
ID=10795775
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50255798A Expired - Lifetime JP4359651B2 (ja) | 1996-06-24 | 1997-06-24 | マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少 |
| JP50255898A Expired - Lifetime JP4162263B2 (ja) | 1996-06-24 | 1997-06-24 | フリーラジカル―誘発状態を治療するためのキレート化剤およびその金属キレート |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50255798A Expired - Lifetime JP4359651B2 (ja) | 1996-06-24 | 1997-06-24 | マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6258828B1 (enExample) |
| EP (2) | EP0910360B1 (enExample) |
| JP (2) | JP4359651B2 (enExample) |
| CN (2) | CN1228703A (enExample) |
| AT (2) | ATE228361T1 (enExample) |
| AU (2) | AU720621B2 (enExample) |
| BR (1) | BR9709942A (enExample) |
| CA (2) | CA2259150A1 (enExample) |
| DE (2) | DE69717447T2 (enExample) |
| GB (1) | GB9613182D0 (enExample) |
| IL (1) | IL127733A0 (enExample) |
| NO (2) | NO985917L (enExample) |
| NZ (2) | NZ333357A (enExample) |
| WO (2) | WO1997049390A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001527072A (ja) | 1997-12-23 | 2001-12-25 | ニユコメド・イメージング・アクシエセルカペト | 一酸化窒素を放出するキレート化剤およびその治療上の使用 |
| GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| KR101353140B1 (ko) | 1999-10-01 | 2014-01-20 | 디엠아이 바이오사이언시스, 인크 | 금속 결합 화합물 및 그의 용도 |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| FR2823977B1 (fr) * | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
| FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| ES2388064T3 (es) | 2004-04-22 | 2012-10-08 | Celator Pharmaceuticals, Inc. | Formulaciones liposomales de agentes de antraciclina y análogos de citidina |
| CA2880727C (en) | 2005-08-31 | 2019-05-07 | Neil P. Desai | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| WO2009078794A1 (en) * | 2007-12-14 | 2009-06-25 | Pledpharma Ab | Compounds for use in the treatment of cancer |
| EP2451457B1 (en) | 2009-07-06 | 2018-03-07 | Pledpharma AB | Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound |
| ES2792062T3 (es) | 2011-05-09 | 2020-11-06 | Mayo Found Medical Education & Res | Tratamientos contra el cáncer |
| CA2862736C (en) | 2012-01-05 | 2020-09-08 | Pledpharma Ab | Mixed metal complexes and methods |
| ES2899643T3 (es) | 2012-10-01 | 2022-03-14 | Mayo Found Medical Education & Res | Tratamientos para el cáncer |
| MX376321B (es) | 2012-11-02 | 2025-03-07 | Egetis Therapeutics Ab | Usos para el tratamiento de cancer. |
| AU2015274408A1 (en) | 2014-06-13 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating lymphomas |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| WO2017165439A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| CA3035378A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Carrier-pd-l1 binding agent compositions for treating cancers |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| AU2017324335A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES444380A1 (es) * | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US5223243A (en) * | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| US4842845A (en) * | 1987-05-08 | 1989-06-27 | Salutar, Inc. | Radioactive metal chelates for dipyridoxyl phosphate |
| US4935518A (en) * | 1987-05-08 | 1990-06-19 | Salutar, Inc. | Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof |
| US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
-
1996
- 1996-06-24 GB GBGB9613182.6A patent/GB9613182D0/en active Pending
-
1997
- 1997-06-24 WO PCT/GB1997/001721 patent/WO1997049390A1/en not_active Ceased
- 1997-06-24 WO PCT/GB1997/001722 patent/WO1997049409A1/en not_active Ceased
- 1997-06-24 DE DE69717447T patent/DE69717447T2/de not_active Expired - Lifetime
- 1997-06-24 IL IL12773397A patent/IL127733A0/xx unknown
- 1997-06-24 CN CN97197438A patent/CN1228703A/zh active Pending
- 1997-06-24 EP EP97928368A patent/EP0910360B1/en not_active Expired - Lifetime
- 1997-06-24 JP JP50255798A patent/JP4359651B2/ja not_active Expired - Lifetime
- 1997-06-24 CA CA002259150A patent/CA2259150A1/en not_active Abandoned
- 1997-06-24 AU AU32689/97A patent/AU720621B2/en not_active Ceased
- 1997-06-24 JP JP50255898A patent/JP4162263B2/ja not_active Expired - Lifetime
- 1997-06-24 DE DE69716104T patent/DE69716104T2/de not_active Expired - Lifetime
- 1997-06-24 NZ NZ333357A patent/NZ333357A/xx unknown
- 1997-06-24 AT AT97928368T patent/ATE228361T1/de not_active IP Right Cessation
- 1997-06-24 CN CN97197429A patent/CN1228694A/zh active Pending
- 1997-06-24 EP EP97928369A patent/EP0936915B1/en not_active Expired - Lifetime
- 1997-06-24 AT AT97928369T patent/ATE225178T1/de not_active IP Right Cessation
- 1997-06-24 BR BR9709942A patent/BR9709942A/pt not_active Application Discontinuation
- 1997-06-24 CA CA002258299A patent/CA2258299A1/en not_active Abandoned
- 1997-06-24 NZ NZ333315A patent/NZ333315A/xx unknown
- 1997-06-24 AU AU32688/97A patent/AU720570B2/en not_active Ceased
-
1998
- 1998-12-17 NO NO985917A patent/NO985917L/no not_active Application Discontinuation
- 1998-12-17 NO NO985916A patent/NO985916L/no not_active Application Discontinuation
- 1998-12-17 US US09/213,290 patent/US6258828B1/en not_active Expired - Lifetime
- 1998-12-17 US US09/213,246 patent/US6147094A/en not_active Expired - Lifetime